Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIV-818 in Liver Cancer Manifestations
NCT03781934Phase 2Completed
- Sponsor
- Medivir
- Start
- Sep 2018
- Primary completion
- Jan 2025
- Modality
- Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of Fostroxacitabine bralpamide in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), liver metastases, sponsored by Medivir. Started Sep 2018; status: completed.
02
Drugs
Fostroxacitabine bralpamide
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)liver metastases
Beyond the preview
Go deeper on NCT03781934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781934.